ALNY monthly performance report
Monthly ALNY research: returns, drawdown, relative strength, seasonality, and key stats.
ALNY monthly report
—
Key takeaways
- Alnylam Pharmaceuticals (ALNY) closed September 2026 at $266.11, up 10.56% for the month and −41.33% over the trailing 12 months.
- Year-to-date, ALNY is −33.08%, underperforming the S&P 500 which has returned +12.94% YTD.
- The stock is trading −18.32% versus its 200-day moving average ($325.80), a cautious technical signal.
- Over the past three years, ALNY has underperformed the S&P 500 by −38.42%, with a relative strength index reading of 77.5.
- Win rate over the trailing 39 months stands at 51.3% — 20 positive months versus 19 negative months.
Alnylam Pharmaceuticals ended September 2026 at $266.11, posting a monthly return of +10.56%. The S&P 500 returned +0.41% over the same window, leaving relative performance at +10.15%.
The current quarter stands at −15.71% (Q3 2026 (QTD)), while medium-term trend remains soft: price is −18.32% versus the 200-day moving average ($325.80).
Year-to-date, ALNY is −33.08% against SPY +12.94%, a gap of −46.02%. The stock is currently −46.30% below its 52-week high, with maximum 3-year drawdown at −58.17%.
| Period | ALNY | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | −0.48% | +0.66% | −1.14% |
| 1 Week | +10.84% | −0.12% | +10.96% |
| 1 Month | +10.56% | +0.41% | +10.15% |
| 3 Months | −9.99% | +2.11% | −12.10% |
| 6 Months | −20.07% | +13.21% | −33.28% |
| YTD | −33.08% | +12.94% | −46.02% |
| 12 Months | −41.33% | +18.65% | −59.98% |
| 3 Years | +32.28% | +70.70% | −38.42% |
| Rank | Month | Return |
|---|---|---|
| #1 | Jun 2024 | +62.87% |
| #2 | Jul 2025 | +20.77% |
| #3 | May 2025 | +18.44% |
| #4 | Aug 2026 | +15.69% |
| #5 | Aug 2025 | +14.88% |
| Rank | Month | Return |
|---|---|---|
| #1 | Jul 2026 | −32.51% |
| #2 | Jan 2026 | −15.35% |
| #3 | Oct 2023 | −14.39% |
| #4 | Feb 2024 | −12.94% |
| #5 | Dec 2025 | −11.63% |
| Quarter | Return |
|---|---|
| Q2 2025 | +23.09% |
| Q3 2025 | +41.91% |
| Q4 2025 | −12.28% |
| Q1 2026 | −16.10% |
| Q2 2026 | −8.34% |
| Q3 2026 (QTD) | −15.71% |
| Year | Return |
|---|---|
| 2023 | −18.79% |
| 2024 | +19.99% |
| 2025 | +74.64% |
| 2026 | −35.18% |
| Metric | Value |
|---|---|
| 52-Week High | $495.55 (2025-10-20) |
| 52-Week Low | $197.81 (2026-07-30) |
| Current Price | $266.11 |
| 200-Day Moving Average | $325.80 |
| Price vs 200DMA | −18.32% |
| 3-Year Maximum Drawdown | −58.17% (2026-07-30) |
| Current Drawdown from 52W High | −46.30% |
| RS metric | Value |
|---|---|
| RS Index (3-year, rebased to 100) | 77.5 |
| 3-Year Excess Return vs S&P 500 | −38.42% |
| RS Peak | 166.2 (Sep 2025) |
| RS Trough | 61.7 (Jul 2026) |
| Status | Underperforming Benchmark |
Frequently asked questions
What was ALNY's return for this report period?
ALNY returned +10.56% in the latest monthly window ending 2026-09-04.
Has ALNY outperformed SPY year to date?
YTD ALNY: −33.08% vs SPY: +12.94%.
What is ALNY's 12-month return?
−41.33% over the trailing 12 months.
Is ALNY above or below its 200-day moving average?
Price is −18.32% versus 200DMA ($325.80).
What is the maximum drawdown in the 3-year window?
−58.17% on 2026-07-30.